Senti Biosciences amends ChEF purchase agreement to allow intraday VWAP share sales under $50M facility

Senti Biosciences, Inc.

Entered amended ChEF purchase agreement with Chardan Capital Markets for existing $50M equity facility.
Amendment permits intraday volume-weighted average price (VWAP) purchases of common stock.
The change gives the company flexibility to sell shares more frequently under the facility.
Shares sold under the agreement are restricted securities and resale registered under Registration Rights Agreement.
The Agreement amends and restates the original August 31, 2022 ChEF Purchase Agreement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.